文献速递银屑病与炎症性皮肤病

IL-6与TNF-α不同:银屑病中IL-6阻断引发的意外临床效应

IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis.
PubMed 文献 · J Invest Dermatol · 2017-01-01

本文探讨IL-6在银屑病中的作用。IL-6在银屑病患者血清和皮损中升高,但抗IL-6疗法对银屑病无效或可诱发新发银屑病样疾病。Fritz等通过IL-6缺陷小鼠的IL-17C驱动银屑病样疾病模型提供解释:小鼠初期发病较慢,但随后恶化,提示IL-6缺乏导致其他细胞因子代偿性促炎效应,最终加重银屑病炎症。

要点

  • IL-6在银屑病血清和皮损中升高,但抗IL-6治疗对银屑病无效或可诱发银屑病样病。
  • IL-6缺陷小鼠中IL-17C驱动银屑病样病初期较轻但后期加重。
  • IL-6缺乏可能引起其他细胞因子代偿性促炎,最终加重炎症。

核心结论

  • IL-6阻断在银屑病中可能无效或诱发银屑病样疾病,IL-6缺乏可导致代偿性促炎效应使炎症恶化。

研究设计与样本

  • Fritz等在小鼠IL-6缺陷遗传背景下研究IL-17C驱动的银屑病样疾病。

主要发现

  • IL-6缺陷小鼠初期皮肤病变出现较慢,但随后随时间恶化。

临床怎么用

  • 提示抗IL-6疗法不适用于银屑病,临床需注意其可能诱发银屑病样疾病。

局限性

  • 证据来自小鼠模型,临床观察为间接支持,需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IL-6 is a pleiotropic proinflammatory cytokine that is elevated in serum and skin lesions of patients with psoriasis. Anti-IL-6 therapies, however, which are effective for rheumatoid arthritis, are either ineffective for psoriasis or can induce new-onset psoriasis-like disease. Fritz et al. provide a potential explanation for these clinical observations by examining IL-17C-driven psoriasis-like disease in mice with an IL-6-deficient genetic background. These mice displayed slower onset skin disease initially, but then worsened over time, suggesting that a lack of IL-6 led to compensatory proinflammatory effects by other cytokines, which eventually worsened the psoriatic inflammation.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A. IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis. J Invest Dermatol. 2017. PMID: 28235443. doi:10.1016/j.jid.2016.11.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。